A new spinout, Atrium Therapeutics, launched with approximately $270 million in cash and assets carved out from Avidity Biosciences to pursue RNA therapeutics for rare genetic cardiomyopathies. The company took two lead candidates into its pipeline: ATR‑1072 for PRKAG2 syndrome (siRNA) and ATR‑1086 for PLN cardiomyopathy, both leveraging antibody‑oligonucleotide conjugate (AOC) delivery chemistry. Atrium plans a first‑in‑human IND for ATR‑1072 in the latter half of the year and aims to submit an IND for ATR‑1086 in 2027. Management emphasized that the deal preserves tissue‑targeting know‑how while focusing resources on cardiac indications that have high unmet need. The spinout signals continued industry interest in targeted oligonucleotide delivery to non‑hepatic tissues and highlights how large M&A deals can generate downstream startups addressing niche therapeutic areas.